Abbott gains national CMS coverage for tricuspid valve repair

Abbott gains national CMS coverage for tricuspid valve repair

The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid regurgitation, in which blood can leak backward into the heart.

CMS Issues NCD for Abbott’s TriClip Device

Abbott’s TriClip G5 device will now be covered by Medicare, ensuring long-term, predictable access to a minimally invasive treatment option for eligible Medicare and Medicare Advantage beneficiaries.

CMS Approves Coverage for T-TEER to Treat Tricuspid Regurgitation - Cardiac Interventions Today

July 11, 2025—The United States Centers for Medicare & Medicaid Services (CMS) recently announced it has issued a National Coverage Determination (NCD) that covers FDA-approved tricuspid transcatheter edge-to-edge repair (T-TEER) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED), when furnished in accordance with the coverage criteria specified in the NCD. The complete NCD decision memor…